Rechallenge with clozapine following leucopenia or neutropenia during previous therapy

The British Journal of Psychiatry : the Journal of Mental Science
Louisa R DunkChristopher D Andrews

Abstract

Further treatment with clozapine is contraindicated in any patient who has previously experienced leucopenia or neutropenia during clozapine therapy. To investigate the results of such a rechallenge in 53 patients. An analysis was made of the demographic, haematological and outcome data of patients in the UK and Ireland who were rechallenged with clozapine following leucopenia or neutropenia during previous clozapine therapy. Of 53 patients who were rechallenged, 20 (38%) experienced a further blood dyscrasia. In 17 of these 20 patients (85%) the second blood dyscrasia was more severe (P<0.001), in 12 (60%) it lasted longer (P=0.0368) and in 17 (85%) it occurred more quickly on rechallenge (P<0.001). Of the original 53 patients, 55% (29 patients) are still receiving clozapine. No clear risk factor for repeat blood dyscrasias was identified. Despite this, after risks and benefits have been considered, rechallenge may well be justified in some patients.

References

Mar 11, 1977·European Journal of Clinical Pharmacology·J Idänpään-HeikkiläI P Palva
May 23, 1992·Lancet·A Z SaffermanA Howard
Jan 1, 1992·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S L Gerson, H Meltzer
Aug 6, 1991·Lancet·S L GersonH Meltzer
Oct 1, 1990·Archives of General Psychiatry·J A LiebermanE J Yunis
Dec 1, 1994·Journal of Clinical Psychopharmacology·F R FrankenburgS L Gerson
Jun 1, 1993·Journal of Clinical Psychopharmacology·A Z SaffermanK Rai
Jan 1, 1993·International Clinical Psychopharmacology·A ValevskiA Weizman
Jul 15, 1993·The New England Journal of Medicine·S L Gerson
Jan 1, 1996·Psychiatric Services : a Journal of the American Psychiatric Association·E BarronsP Nynkowski
Apr 16, 1998·The British Journal of Psychiatry : the Journal of Mental Science·B Sperner-UnterwegerW W Fleischhacker
May 2, 2000·The British Journal of Psychiatry : the Journal of Mental Science·J MunroR Kerwin
Apr 13, 2004·International Clinical Psychopharmacology·Yong Min AhnYong Sik Kim

❮ Previous
Next ❯

Citations

Sep 28, 2010·Irish Journal of Medical Science·Z LatifC McDonough
May 14, 2008·Southern Medical Journal·Tricia G Majczenko, Jonathan T Stewart
Aug 7, 2008·Pharmacogenomics·Carolin Opgen-Rhein, Michael Dettling
Jun 15, 2011·The Australian and New Zealand Journal of Psychiatry·Les Drew
Oct 1, 2007·Indian Journal of Psychiatry·Ram K SolankiMukesh K Swami
Nov 8, 2011·Irish Journal of Medical Science·J P A M BogersB Bakker
Aug 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·D EspositoE Corruble
Feb 23, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Vid StanulovićBrian Edwards
Nov 27, 2014·Expert Opinion on Drug Metabolism & Toxicology·Alexander Johnston, Jack Uetrecht
May 22, 2016·Asian Journal of Psychiatry·Tarun BastiampillaiStephen Allison
Apr 15, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Szu-Ying WuMing H Hsieh
Jan 29, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ana Cristina ChavesNatalia Joelsman Timerman
Apr 3, 2014·Early Intervention in Psychiatry·Gabrielle Crépeau-Gendron, Sophie L'heureux
Feb 12, 2013·General Hospital Psychiatry·Andreia W P HazewinkelErik J Giltay
May 28, 2016·Journal of Clinical Psychopharmacology·Cintia R ProkopezFederico M Daray
Oct 25, 2016·Chemical Research in Toxicology·Tiffany Cho, Jack Uetrecht
Jun 28, 2013·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Leslie Drew
Apr 19, 2017·The Pharmacogenomics Journal·S A J de WithR A Ophoff
Oct 30, 2013·Therapeutic Advances in Psychopharmacology·Al Aditya KhanSamrat Sengupta
Oct 30, 2013·Therapeutic Advances in Psychopharmacology·Emerson Arcoverde NunesJaime E C Hallak
May 18, 2010·Journal of Clinical Psychopharmacology·Laure RagonnetSonia Dollfus
Nov 16, 2007·Journal of Clinical Psychopharmacology·Karen A Mathewson, J-P Lindenmayer
Dec 22, 2007·Human Psychopharmacology·Robert J Flanagan, Louisa Dunk
Nov 18, 2008·Journal of Clinical Psychopharmacology·Karine Charbonneau, Pierre Landry
Aug 18, 2017·Journal of Clinical Psychopharmacology·John LallyJames H MacCabe
Mar 6, 2018·American Journal of Therapeutics·Peter ManuJimmi Nielsen
Apr 6, 2019·BMJ Case Reports·Suraj PathakAmbreen Aftab
Sep 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·P Soma, P C Naik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here